We continue to develop resources related to the COVID-19 pandemic. See COVID-19 initiatives on Appropedia for more information.
Rapid Strip Assay (RDT) for Gestational Diabetes Mellitus
|Health Topic||Maternal mortality|
Problem being addressed
Gestational diabetes mellitus (GDM) occurs due to uncontrollable levels of blood glucose with onset or first recognition during pregnancy. This can cause several serious health problems for both mother and child, including the predisposition of Type 2 diabetes. The current tests in place to regulate glucose levels often demand fasting and multiple hours to complete, leading to low patient compliance.
Detailed description of the solution
The Rapid Strip Assay (RDT) is meant to identify a new biomarker, glycated albumin, which can diagnose GDM within several minutes. This allows a cheaper and faster method to determine if pregnant mothers or their babies will develop diabetes. Following the test, patients can be counseled on diet, exercise, further screening, or insulin ingestion based on the test results.
- Designed by: PATH, University of Washington Laboratory of Medicine
- Manufacturer location: Seattle, Washington USA, India
When and where it was tested/implemented
Project from 2011-2013, Seattle, WA USA and India
Health Innovation Portfolio, The Saving Life at Birth Consortium, Madras Diabetes Research Foundation
Other internally generated reports
Path. Gestational Diabetes. Retrieved November 13 2013 from here.
Path. (July 2012). Rapid screening test for gestational diabetes. Retrieved November 13 2013 from here.
Externally generated reports
Saving Lives at Birth. (2011). Strip test for glycated albumin screening. Retrieved November 13 2013 from here.